Large Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LRG001 MIFTS: 45	Large Cell Carcinoma Categories: Cancer diseases, Genetic diseases, Mental diseases, Rare diseases, Respiratory diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Large Cell Carcinoma

MalaCards integrated aliases for Large Cell Carcinoma:

Name: Large Cell Carcinoma ¹¹ ¹⁴

Carcinoma, Large Cell ⁴³ ⁷¹

Carcinoma Large Cell ⁵³

Classifications:

MalaCards categories:
Global: Cancer diseases Genetic diseases Rare diseases
Anatomical: Skin diseases Respiratory diseases Mental diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:4552

MeSH ⁴³ D018287

NCIt ⁴⁹ C3780

SNOMED-CT ⁶⁸ 22687000

UMLS ⁷¹ C0206704

Sources

Summaries for Large Cell Carcinoma

Disease Ontology: ¹¹ A carcinoma that is composed of large, monotonous rounded or overtly polygonal-shaped cells with abundant cytoplasm.

MalaCards based summary: Large Cell Carcinoma, also known as carcinoma, large cell, is related to thymus large cell carcinoma and large cell carcinoma with rhabdoid phenotype. An important gene associated with Large Cell Carcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Endometrial cancer and NF-kappaB Pathway. The drugs Everolimus and Erlotinib have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and lymph node, and related phenotypes are Decreased viability and homeostasis/metabolism

Sources

Related Diseases for Large Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1	Basal Cell Carcinoma 2
Basal Cell Carcinoma 3	Basal Cell Carcinoma 4
Basal Cell Carcinoma 5	Basal Cell Carcinoma 6
Basal Cell Carcinoma 7	Basal Cell Carcinoma
Large Cell Carcinoma	Basal Cell Carcinoma, Multiple

Diseases related to Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 671)

#	Related Disease	Score	Top Affiliating Genes
1	thymus large cell carcinoma	32.8	SYP KRT7 KRT5 CHGA
2	large cell carcinoma with rhabdoid phenotype	32.6	KRAS HRAS ENO2
3	lung large cell carcinoma	32.6	SYP NKX2-1 KRT7 KRT5 KRAS HRAS
4	pleomorphic carcinoma	31.9	NKX2-1 KRT7 KRT5 KRAS HRAS EGFR
5	large cell neuroendocrine carcinoma	31.9	SYP NKX2-1 KRT7 KRT5 KRAS HRAS
6	lung cancer	31.2	UCHL1 TP63 SYP SFTPB PTHLH NKX2-1
7	neuroendocrine carcinoma	30.9	TP63 SYP NKX2-1 MUC1 KRT7 KRT20
8	lung giant cell carcinoma	30.8	NKX2-1 KRT7 KRT5 KRAS EGFR
9	small cell cancer of the lung	30.8	SYP NKX2-1 KRT7 KRT20 ENO2 EGFR
10	carcinoid syndrome	30.7	SYP ENO2 CHGA
11	small cell carcinoma	30.7	SYP NKX2-1 KRT7 KRT5 KRT20 ENO2
12	carcinoid tumors, intestinal	30.7	SYP NKX2-1 ENO2 CHGA
13	neuroendocrine tumor	30.6	SYP PTHLH NKX2-1 KRT20 ENO2 CHGA
14	bronchus cancer	30.6	KRT7 ERBB2 ENO2 EGFR CEACAM5
15	lymphoepithelioma-like carcinoma	30.6	SYP KRT7 KRT5 KRT20 ENO2 EGFR
16	pulmonary large cell neuroendocrine carcinoma	30.6	SYP NKX2-1 ENO2 CHGA
17	basaloid squamous cell carcinoma	30.5	SYP NKX2-1 KRT7 KRT5 ENO2 CHGA
18	lung benign neoplasm	30.5	SYP NKX2-1 KRT7 KRT20 KRAS HRAS
19	intestinal obstruction	30.5	KRT7 KRT20 CEACAM5
20	adenocarcinoma	30.4	NKX2-1 MUC1 KRT7 KRT20 KRAS HRAS
21	rectum cancer	30.3	KRT20 KRAS HRAS EGFR CEACAM5 CEACAM3
22	lung squamous cell carcinoma	30.3	PTHLH KRAS HRAS EGFR CEACAM5
23	trachea carcinoma	30.3	NKX2-1 KRT7 KRT5 CEACAM5
24	solid adenocarcinoma with mucin production	30.2	NKX2-1 MUC1 KRT7 KRT5 CHGA
25	rectal benign neoplasm	30.2	KRT7 KRT20 KRAS HRAS EGFR CEACAM5
26	neurofibromatosis, type i	30.2	KRAS HRAS ENO2 EGFR
27	squamous cell carcinoma	30.2	TP63 PTHLH NKX2-1 MUC1 KRT7 KRAS
28	thymic carcinoma	30.1	TP63 SYP NKX2-1 MUC1 KRT7 KRT5
29	tubular adenocarcinoma	30.1	SYP MUC1 KRT7 KRT20 ERBB2 ENO2
30	benign mesothelioma	30.1	NKX2-1 KRT7 KRT5 KRT20 CEACAM5
31	vulva cancer	30.1	KRT7 HRAS ERBB2 EGFR CEACAM5
32	bladder urothelial carcinoma	30.1	KRT20 KRAS HRAS ERBB2
33	melanoma, uveal	30.1	HRAS ERBB2 EGFR CDK4
34	thymus cancer	30.1	NKX2-1 KRT7 KRT5 HRAS ERBB2 EGFR
35	skin benign neoplasm	30.0	TP63 KRT7 KRT5 KRT20 HRAS ENO2
36	suppression of tumorigenicity 12	30.0	SYP KRT5 HRAS ERBB2 ENO2 EGFR
37	squamous cell carcinoma, head and neck	29.9	TP63 HRAS ERBB2 EGFR CDK4
38	bronchiolo-alveolar adenocarcinoma	29.9	NKX2-1 KRT7 KRT20 KRAS HRAS EGFR
39	signet ring cell adenocarcinoma	29.8	MUC1 KRT7 KRT20 KRAS HRAS ERBB2
40	peripheral nervous system disease	29.8	UCHL1 SYP KRAS HRAS ERBB2 ENO2
41	lung cancer susceptibility 3	29.7	TP63 SFTPB NKX2-1 MUC1 KRT7 KRT20
42	adenosquamous carcinoma	29.7	TP63 PTHLH NKX2-1 MUC1 KRT7 KRT5
43	mesothelioma, malignant	29.6	TP63 SFTPB NKX2-1 MUC1 KRT7 KRT5
44	adenoid cystic carcinoma	29.6	TP63 MUC1 KRT7 KRT20 KRAS HRAS
45	gastric cancer	29.5	MUC1 KRT20 KRAS ERBB2 EGFR CHGA
46	ovarian cancer	29.5	MUC1 KRT7 KRT20 KRAS HRAS ERBB2
47	prostate cancer	29.3	TP63 PTHLH MUC1 KRT5 HRAS ERBB2
48	lung occult large cell carcinoma	11.3
49	lung mixed small cell and squamous cell carcinoma	11.2
50	large cell keratinizing variant squamous cell breast carcinoma	11.2

Graphical network of the top 20 diseases related to Large Cell Carcinoma:

Sources

Symptoms & Phenotypes for Large Cell Carcinoma

GenomeRNAi Phenotypes related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 11)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	9.62	EGFR HRAS KRAS MUC1
2	Decreased viability	GR00055-A-2	9.62	EGFR HRAS KRAS MUC1
3	Decreased viability	GR00055-A-3	9.62	KRAS
4	Decreased viability	GR00106-A-0	9.62	KRAS
5	Decreased viability	GR00221-A-1	9.62	EGFR HRAS KRAS
6	Decreased viability	GR00221-A-2	9.62	HRAS KRAS
7	Decreased viability	GR00221-A-3	9.62	HRAS
8	Decreased viability	GR00221-A-4	9.62	EGFR
9	Decreased viability	GR00249-S	9.62	MUC1
10	Decreased viability	GR00301-A	9.62	KRAS
11	Decreased viability	GR00381-A-1	9.62	KRAS

MGI Mouse Phenotypes related to Large Cell Carcinoma:

⁴⁵ (show all 15)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.33	CDK4 CEACAM5 CGB5 CHGA EGFR ERBB2
2	growth/size/body region	MP:0005378	10.28	CDK4 CEACAM5 CGB5 CHGA EGFR ENO2
3	neoplasm	MP:0002006	10.25	CDK4 CEACAM5 EGFR ERBB2 HRAS KRAS
4	normal	MP:0002873	10.24	CDK4 EGFR ERBB2 HRAS KRAS MUC1
5	endocrine/exocrine gland	MP:0005379	10.18	CDK4 CEACAM5 CGB5 CHGA EGFR ERBB2
6	renal/urinary system	MP:0005367	10.16	CDK4 CHGA EGFR HRAS KRAS KRT7
7	digestive/alimentary	MP:0005381	10.15	CDK4 CEACAM5 EGFR ERBB2 HRAS KRAS
8	muscle	MP:0005369	10.1	CDK4 CEACAM5 CHGA EGFR ERBB2 HRAS
9	no phenotypic analysis	MP:0003012	10.07	CHGA EGFR HRAS KRAS MUC1 NKX2-1
10	limbs/digits/tail	MP:0005371	10.02	EGFR ERBB2 KRAS KRT5 PTHLH TP63
11	cardiovascular system	MP:0005385	10	CDK4 CEACAM5 CHGA EGFR ERBB2 HRAS
12	craniofacial	MP:0005382	9.97	CDK4 EGFR ENO2 ERBB2 HRAS KRAS
13	behavior/neurological	MP:0005386	9.97	CDK4 CEACAM5 ENO2 ERBB2 HRAS KRAS
14	respiratory system	MP:0005388	9.65	EGFR ENO2 ERBB2 HRAS KRAS NKX2-1
15	integument	MP:0010771	9.32	CDK4 EGFR ERBB2 HRAS KRAS KRT5

Sources

Drugs & Therapeutics for Large Cell Carcinoma

Drugs for Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Everolimus

Approved

Phase 4

159351-69-6

70789204 6442177

Erlotinib

Approved, Investigational

Phase 3

183319-69-9, 183321-74-6

176870

Protein Kinase Inhibitors

Phase 3

Insulin, Globin Zinc

Phase 3

Insulin

Phase 3

Immunoglobulins

Phase 3

Antibodies, Monoclonal

Phase 3

Antibodies

Phase 3

Mitogens

Phase 3

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Carboplatin

Approved

Phase 1, Phase 2

41575-94-4

10339178 38904

Paclitaxel

Approved, Vet_approved

Phase 1, Phase 2

33069-62-4

36314

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Nivolumab

Approved

Phase 2

946414-94-4

Etoposide

Approved

Phase 2

33419-42-0

36462

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Picropodophyllin

Approved, Investigational

Phase 2

518-28-5, 477-47-4

10607 72435

Temozolomide

Approved, Investigational

Phase 2

85622-93-1

5394

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Veliparib

Investigational

Phase 1, Phase 2

912444-00-9

11960529

Pharmaceutical Solutions

Phase 2

Vaccines

Phase 1, Phase 2

Folic Acid Antagonists

Phase 2

Folate

Phase 2

Vitamin B9

Phase 2

Vitamin B Complex

Phase 2

Albumin-Bound Paclitaxel

Phase 1, Phase 2

Antimitotic Agents

Phase 2

Tubulin Modulators

Phase 2

Immunologic Factors

Phase 2

Immune Checkpoint Inhibitors

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Immunoglobulins, Intravenous

Phase 2

Immunoglobulin G

Phase 2

Etoposide phosphate

Phase 2

16760419

Adjuvants, Immunologic

Phase 2

Keratolytic Agents

Phase 2

Angiogenesis Inhibitors

Phase 2

Dermatologic Agents

Phase 2

Endothelial Growth Factors

Phase 2

Poly(ADP-ribose) Polymerase Inhibitors

Phase 1, Phase 2

Alkylating Agents

Phase 2

Antineoplastic Agents, Alkylating

Phase 2

Crizotinib

Approved, Investigational

Phase 1

877399-52-5

11626560

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 1

133585-56-5, 60-18-4, 556-02-5

1153 6057

Interventional clinical trials:

(show all 17)

#	Name	Status	NCT ID	Phase	Drugs
1	Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)	Completed	NCT02151149	Phase 4	nab-paclitaxel;Carboplatin
2	A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC)	Completed	NCT01317615	Phase 4	RAD001;Paclitaxel;Carboplatin
3	Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology	Terminated	NCT00673049	Phase 3	CP 751,871 (Figitumumab);Erlotinib
4	Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer	Terminated	NCT00596830	Phase 3	CP-751,871 (Figitumumab);Carboplatin;Paclitaxel
5	A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment	Unknown status	NCT01497041	Phase 2	Docetaxel;Oxaliplatin
6	A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer	Completed	NCT00073398	Phase 1, Phase 2
7	A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer	Recruiting	NCT05198830	Phase 2	Cisplatin;Methoxyamine;Pemetrexed
8	Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR	Active, not recruiting	NCT03110978	Phase 2
9	A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer	Active, not recruiting	NCT00334815	Phase 2	Cisplatin;Docetaxel;Etoposide
10	A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)	Active, not recruiting	NCT01386385	Phase 1, Phase 2	Carboplatin;Paclitaxel;Veliparib
11	A Randomized Phase 2 Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients	Terminated	NCT00632203	Phase 2	Temozolomide
12	A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer	Completed	NCT02535325	Phase 1	Cisplatin;Methoxyamine;Methoxyamine Hydrochloride;Pemetrexed;Pemetrexed Disodium
13	An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer	Recruiting	NCT04432207	Phase 1	IMU-201 (administered as PD1-Vaxx)
14	A Phase 1, Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Combined Oral C-Met/ALK Inhibitor (PF-02341066) and Pan-Her Inhibitor (PF-0299804) in Patients With Advanced Non-Small Cell Lung Cancer	Terminated	NCT01441128	Phase 1	PF-02341066/PF-00299804
15	Use of Social Networking to Survey Women With Small and Large Cell Carcinomas of the Cervix	Unknown status	NCT01606293
16	A Multicenter, Single-blind, Pair-matched, Observational Clinical Trial of LUNSAFE	Recruiting	NCT05337163
17	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)	Recruiting	NCT02194738		Carboplatin;Cisplatin;Crizotinib;Erlotinib;Gemcitabine Hydrochloride;Paclitaxel;Pemetrexed;Pemetrexed Disodium

Search NIH Clinical Center for Large Cell Carcinoma

Cochrane evidence based reviews: carcinoma, large cell

Sources

Genetic Tests for Large Cell Carcinoma

Sources

Anatomical Context for Large Cell Carcinoma

Organs/tissues related to Large Cell Carcinoma:

MalaCards : Lung, Cervix, Lymph Node, Endothelial, Brain, Thyroid, Small Intestine

Sources

Publications for Large Cell Carcinoma

Articles related to Large Cell Carcinoma:

(show top 50) (show all 1836)

#	Title	Authors	PMID	Year
1	Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. ⁵³ ⁶²	Ren XL...Yang AG	19339104	2009
2	[Poorly differentiated large cell endocrine carcinoma of the extrahepatic bile ducts]. ⁵³ ⁶²	Demoreuil C...Buffet C	19233580	2009
3	Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. ⁵³ ⁶²	Molina JR...Adjei AA	18452692	2008
4	Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin. ⁵³ ⁶²	Liang CH...Kuo KW	18078328	2008
5	[Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci]. ⁵³ ⁶²	Bai XY...Shen H	18227018	2008
6	Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. ⁵³ ⁶²	Petrovic M...Baskic D	18404793	2008
7	Humoral hypercalcemia of malignancy in a patient with large cell carcinoma of the lung: report of case and review of literature. ⁵³ ⁶²	Makdissi A...Zimmerman RS	17669716	2007
8	Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. ⁵³ ⁶²	Sonobe M...Tanaka F	17192868	2007
9	[Quantitative study of thyroid transcription factor-1 protein expression in lung carcinoma cell nucleus by tissue microarray]. ⁵³ ⁶²	Bai XY...Shen H	17062341	2006
10	[EGFR and HER2 gene expression status and their correlation in non-small cell lung cancer]. ⁵³ ⁶²	Zeng X...Liu TH	17069674	2006
11	Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. ⁵³ ⁶²	Sugio K...Yasumoto K	16552419	2006
12	Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. ⁵³ ⁶²	Nakamura H...Kabasawa K	15770690	2005
13	CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. ⁵³ ⁶²	Mazziotta RM...Mansukhani M	15722794	2005
14	Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. ⁵³ ⁶²	Johansson L	15494931	2004
15	Metastatic bronchogenic carcinoma with human chorionic gonadotropin production manifesting as cerebellar hemorrhage--case report. ⁵³ ⁶²	Sawa H...Nishimura R	11561353	2001
16	The significance of NSE and CEA as a differentiation marker for the cellular heterogeneity of small cell lung cancer. ⁵³ ⁶²	Kobayashi S...Fujimura S	10622207	1999
17	Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression. ⁵³ ⁶²	Wertzel H...Bohm N	9458138	1997
18	Expression and localization of thrombomodulin in preneoplastic bronchial lesions and in lung cancer. ⁵³ ⁶²	Tolnay E...Muller KM	9099977	1997
19	Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP). ⁵³ ⁶²	Manzano RG...Twentyman PR	9816303	1996
20	GRP receptors are present in non small cell lung cancer cells. ⁵³ ⁶²	Moody TW...Hu V	8806107	1996
21	The expression of trophoblastic cell markers by lung carcinomas. ⁵³ ⁶²	Boucher LD...Yoneda K	7590693	1995
22	Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. ⁵³ ⁶²	Ota E...Ogata T	7669560	1995
23	Detection of thrombomodulin in human lung cancer cells. ⁵³ ⁶²	Tamura A...Aoki N	8380956	1993
24	Pulmonary large cell carcinoma expressing neuroendocrine markers: the morphological, biological, and neuroendocrine features of their cell lines and surgical cases. ⁵³ ⁶²	Kasai K...Itoh H	1331003	1992
25	Carcinoembryonic antigen content in fine needle aspirates of the lung. A diagnostic adjunct to cytology. ⁵³ ⁶²	Pinto MM...Ha DJ	1580109	1992
26	Immunohistochemical detection of cluster 1 small cell lung cancer antigen and chromogranin A in lung carcinomas. ⁵³ ⁶²	Noguchi M...Shimosato Y	1315401	1992
27	Activated protooncogenes in human lung tumors from smokers. ⁵³ ⁶²	Reynolds SH...Anderson MW	1996309	1991
28	Comparison of cytologic markers for automated lung cancer screening. ⁵³ ⁶²	Uei Y...Noguchi Y	1702634	1990
29	Large cell carcinoma of the lung secreting human chorionic gonadotropin which responded to combination chemotherapy: case report. ⁵³ ⁶²	Fukuda M...Saijo N	2174998	1990
30	Large cell carcinoma of the lung. Prognostic implications of histopathologic and immunohistochemical subtyping. ⁵³ ⁶²	Ishida T...Ohta M	2154087	1990
31	The Clinical Characteristics and Treatments for Large Cell Carcinoma Patients Older than 65 Years Old: A Population-Based Study. ⁶²	Yao A...Xie S	36358648	2022
32	CircRNA circ-PDCD11 is highly expressed in lung large-cell carcinoma and predicts poor survival. ⁶²	Ma T...Dong Z	36017647	2022
33	Selective Targeting and Eradication of Various Human Non-Small Cell Lung Cancer Cell Lines Using Self-Assembled Aptamer-Decorated Nanoparticles. ⁶²	Barak D...Livney YD	36015276	2022
34	The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. ⁶²	Wu CF...Chang GR	35609368	2022
35	A multi-classification model for non-small cell lung cancer subtypes based on independent subtask learning. ⁶²	Li J...Zhang G	35715882	2022
36	A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114). ⁶²	Sakashita H...Miyazaki Y	35322551	2022
37	Mandatory Nodal Evaluation During Resection of Clinical T1a Non-Small Cell Lung Cancers. ⁶²	Dezube AR...Jaklitsch MT	34358520	2022
38	Proteomic Analysis of Lung Cancer Types-A Pilot Study. ⁶²	Sugar S...Turiak L	35681609	2022
39	Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. ⁶²	Adib E...Kwiatkowski DJ	35428358	2022
40	Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer. ⁶²	Calabrese F...Hofman P	35456982	2022
41	Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers. ⁶²	Liu CY...Wang CY	35383703	2022
42	Essential Oils and Extracts of Juniperus macrocarpa Sm. and Juniperus oxycedrus L.: Comparative Phytochemical Composition and Anti-Proliferative and Antioxidant Activities. ⁶²	Meringolo L...Tundis R	35448753	2022
43	Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy. ⁶²	Ramos-Paradas J...Paz-Ares L	35329826	2022
44	Cytologic presentation of ovarian large cell carcinoma with rhabdoid features detected on peritoneal washing. Report of one case with cyto-histologic correlation and previously undescribed inactivating SMARCA-4 mutations. ⁶²	Fulciniti F...Mazzucchelli L	34905290	2022
45	Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report. ⁶²	Kito Y...Takeuchi T	35151345	2022
46	Pulmonary large cell carcinoma with neuroendocrine morphology shows genetic similarity to large cell neuroendocrine carcinoma. ⁶²	Liang Z...Jiang L	35144629	2022
47	Correlation between the Treg/Thl7 Index and the Efficacy of PD-1 Monoclonal Antibody in Patients with Advanced Non-Small-Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease. ⁶²	Wang X...Shi B	35915772	2022
48	Exploration of the optimal number of regional lymph nodes removed for resected N0 NSCLC patients: A population-based study. ⁶²	Yao A...Xie S	36249000	2022
49	THE PROGNOSIS OF THE DIFFERENT ESOPHAGEAL NEUROENDOCRINE CARCINOMA SUBTYPES: A POPULATION-BASED STUDY. ⁶²	Tustumi F...Dias AR	35442337	2022
50	Case Report: Combined Small Cell Lung Carcinoma With Pulmonary Adenocarcinoma. ⁶²	Shen C...Che G	35187062	2022

Sources

Genes for Large Cell Carcinoma

Genes related to Large Cell Carcinoma (0 elite genes):

(show all 41)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NKX2-1	NK2 Homeobox 1	Protein Coding	23.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18227018 10374779 17062341 (more) 10632746 15494931 12379752 14693848 11956814 10792482 15595193 15722794
2	CHGA	Chromogranin A	Protein Coding	21.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9458138 1315401 19233580 (more) 2170973
3	SYP	Synaptophysin	Protein Coding	21.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9458138
4	ENO2	Enolase 2	Protein Coding	20.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1702634 10622207 7507359 (more) 9458138 18404793 1331003 7523546
5	KRT7	Keratin 7	Protein Coding	19.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15595193 15494931 19859629
6	EGFR	Epidermal Growth Factor Receptor	Protein Coding	14.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16552419 17192868 17721266 (more) 16284218 18452692 15681531 12867060 17069674 14679115
7	PTHLH	Parathyroid Hormone Like Hormone	Protein Coding	14.11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17669716 1935781
8	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	12.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8168034
9	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	12.36	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12173335 11894014 18078328 (more) 19339104 10928158 12867060 17069674 15770690
10	KRT5	Keratin 5	Protein Coding	11.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15494931 12548160
11	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	11.86	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1996309
12	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	11.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	CGB5	Chorionic Gonadotropin Subunit Beta 5	Protein Coding	11.5	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7590693 2174998 11561353
14	TP63	Tumor Protein P63	Protein Coding	11.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15551738 12210069 14612504
15	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	11.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14511407 12606951
16	SFTPB	Surfactant Protein B	Protein Coding	11.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9021728
17	CEACAM3	CEA Cell Adhesion Molecule 3	Protein Coding	11.1	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10622207 2154087 1580109
18	CDK4	Cyclin Dependent Kinase 4	Protein Coding	10.95	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9751261
19	KRT20	Keratin 20	Protein Coding	10.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15494931 19859629
20	UCHL1	Ubiquitin C-Terminal Hydrolase L1	Protein Coding	10.28	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	SFTPC	Surfactant Protein C	Protein Coding	10.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7671236 9020567
22	GRP	Gastrin Releasing Peptide	Protein Coding	9.89	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1702634 8806107
23	MIR200B	MicroRNA 200b	RNA Gene	8.25	DISEASES inferred ¹⁴ ¹⁴
24	MIR126	MicroRNA 126	RNA Gene	8.17	DISEASES inferred ¹⁴ ¹⁴
25	MIR17	MicroRNA 17	RNA Gene	7.9	DISEASES inferred ¹⁴ ¹⁴
26	TIMP2	TIMP Metallopeptidase Inhibitor 2	Protein Coding	7.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10474026
27	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	7.7	DISEASES inferred ¹⁴
28	MIR145	MicroRNA 145	RNA Gene	7.66	DISEASES inferred ¹⁴ ¹⁴
29	STRAP	Serine/Threonine Kinase Receptor Associated Protein	Protein Coding	7.58	GeneCards inferred via : Summaries (show sections)
30	MIR30A	MicroRNA 30a	RNA Gene	7.38	DISEASES inferred ¹⁴ ¹⁴
31	MIR31	MicroRNA 31	RNA Gene	7.35	DISEASES inferred ¹⁴ ¹⁴
32	THBD	Thrombomodulin	Protein Coding	7.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8380956 9099977
33	SFTPD	Surfactant Protein D	Protein Coding	7.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7671236 9020567
34	MIR182	MicroRNA 182	RNA Gene	7.14	DISEASES inferred ¹⁴ ¹⁴
35	ROS1	ROS Proto-Oncogene 1, Receptor Tyrosine Kinase	Protein Coding	7.06	DISEASES inferred ¹⁴
36	EML4	EMAP Like 4	Protein Coding	6.89	DISEASES inferred ¹⁴
37	CDK2	Cyclin Dependent Kinase 2	Protein Coding	6.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9736045
38	NAPSA	Napsin A Aspartic Peptidase	Protein Coding	6.83	DISEASES inferred ¹⁴
39	TP53	Tumor Protein P53	Protein Coding	6.8	DISEASES inferred ¹⁴
40	MIR144	MicroRNA 144	RNA Gene	6.71	DISEASES inferred ¹⁴ ¹⁴
41	MIR30E	MicroRNA 30e	RNA Gene	6.7	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Large Cell Carcinoma

Sources

Expression for Large Cell Carcinoma

Search GEO for disease gene expression data for Large Cell Carcinoma.

Sources

Pathways for Large Cell Carcinoma

Pathways related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 22)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.6	KRAS HRAS ERBB2 EGFR CDK4
2	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.31	KRAS HRAS ERBB2 EGFR
3	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.26	KRAS HRAS ERBB2 EGFR CDK4
4	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.25	MUC1 KRAS HRAS ERBB2 EGFR
5	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.14	KRAS HRAS ERBB2 EGFR
6	Cell surface interactions at the vascular wall ⁶⁶ Show member pathways Fibronectin matrix formation ⁶⁶ PECAM1 interactions ⁶⁶ Tie2 Signaling ⁶⁶	12.11	KRAS HRAS CEACAM5 CEACAM3
7	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.08	KRAS HRAS ERBB2 EGFR CDK4
8	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	11.96	KRAS HRAS ERBB2 EGFR
9	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	11.92	KRAS HRAS ERBB2 EGFR
10	Signaling by PTK6 ⁶⁶ Show member pathways PTK6 Activates STAT3 ⁶⁶ PTK6 Down-Regulation ⁶⁶ PTK6 Expression ⁶⁶ PTK6 promotes HIF1A stabilization ⁶⁶ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁶ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁶ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁶ Signaling by Non-Receptor Tyrosine Kinases ⁶⁶	11.84	KRAS HRAS ERBB2 EGFR CDK4
11	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.83	EGFR ERBB2 HRAS KRAS
12	Gastrin signaling pathway ⁷⁴	11.81	CHGA EGFR HRAS KRAS
13	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁶ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁶ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁶ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁶ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁶	11.72	ERBB2 EGFR CGB5
14	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.38	EGFR ERBB2 HRAS KRAS
15	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.37	EGFR HRAS KRAS
16	a6b1 and a6b4 Integrin signaling ⁶¹	11.29	HRAS ERBB2 EGFR
17	Aryl hydrocarbon receptor pathway ⁷⁴	11.16	KRAS HRAS EGFR
18	Gastrin-CREB signalling pathway via PKC and MAPK ⁶⁶ Show member pathways EGFR Transactivation by Gastrin ⁶⁶	11.01	KRAS HRAS EGFR
19	Bladder cancer ⁷⁴	10.96	KRAS HRAS ERBB2 EGFR CDK4
20	Head and neck squamous cell carcinoma ⁷⁴	10.96	TP63 KRAS HRAS ERBB2 EGFR CDK4
21	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	10.9	KRAS HRAS ERBB2 EGFR
22	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.68	KRAS HRAS

Sources

GO Terms for Large Cell Carcinoma

Biological processes related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell population proliferation	GO:0008284	9.77	TP63 PTHLH KRAS HRAS ERBB2 EGFR
2	epidermis development	GO:0008544	9.63	TP63 PTHLH KRT5 EGFR
3	regulation of long-term neuronal synaptic plasticity	GO:0048169	9.1	SYP KRAS HRAS